FDA Grants Approval for Novitium Pharma's Rifampin ANDA219918
The FDA has granted approval for Novitium Pharma's Abbreviated New Drug Application for Rifampin.
Asset / Drug
Drug and asset intelligence for Rifampin with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.